Analysts Recommend “Moderate Buy” for Sotera Health Shares

Sotera Health Company (NASDAQ:SHC) has received a consensus recommendation of “Moderate Buy” from five research firms currently covering the company, according to Marketbeat.com. This assessment reflects a balance of opinions, with one analyst suggesting a hold on the stock while four analysts advocate for a buy recommendation.

Analysts have set an average one-year price target of $16.00 for Sotera Health. Recent research reports have highlighted the stock’s potential, including a significant upgrade from Wall Street Zen, which raised its rating from “buy” to “strong-buy” on August 16, 2023. Barclays also reaffirmed an “overweight” rating on the shares in a note released on August 8, 2023.

Sotera Health’s latest earnings announcement on August 8, 2023, revealed a quarterly earnings per share (EPS) of $0.20, surpassing the consensus estimate of $0.17 by $0.03. The company reported revenue of $294.34 million for the quarter, exceeding the anticipated $275.81 million. The firm recorded a net margin of 2.14% and a return on equity of 39.42%, with revenue increasing by 6.4% compared to the same quarter the previous year. In the same period last year, Sotera Health achieved an EPS of $0.19. Looking forward, the company has set its fiscal year 2025 guidance at $0.750 to $0.820 EPS.

Insider Transactions and Shareholder Activity

In related news, insider Michael P. Rutz sold 126,611 shares of Sotera Health stock on August 22, 2023, at an average price of $16.38, totaling approximately $2,073,888.18. Following this transaction, Rutz holds 450,204 shares valued at around $7,374,341.52, reflecting a 21.95% decrease in ownership.

Additionally, Director Gtcr Investment Xi LLC sold 8,000,000 shares on September 5, 2023, at an average price of $15.11, amounting to $120,880,000.00. Post-transaction, the director retains 41,215,301 shares valued at approximately $622,763,198.11, indicating a 16.26% reduction in ownership. Over the past three months, insiders have sold a total of 20,126,611 shares worth $304,273,888, with insiders currently owning 55.12% of the company.

Institutional Investment Trends

Recent institutional activity reflects growing interest in Sotera Health. The State of Wyoming increased its stake by 420.6% in the second quarter, acquiring 66,092 shares valued at $735,000. Vident Advisory LLC also raised its position by 23.9%, now owning 17,419 shares valued at $194,000.

Tidal Investments LLC entered a new position valued at $199,000, while Sculptor Capital LP expanded its stake by 27.2%, holding 11,500,000 shares worth $127,880,000. Onex Canada Asset Management Inc. increased its holdings by 61.6%, now owning 414,095 shares valued at $4,605,000. Currently, institutional investors and hedge funds own 91.03% of Sotera Health’s stock.

Sotera Health Company specializes in providing sterilization, lab testing, and advisory services both in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs, offering critical sterilization services including gamma and electron beam irradiation, as well as ethylene oxide processing.

As Sotera Health continues to attract analyst attention and institutional investment, its performance in the coming quarters will be closely monitored by both investors and market analysts.